Correlation Profile of Suppression of Tumorigenicity 2 and/or Interleukin-33 with Biomarkers in the Adipose Tissue of Individuals with Different Metabolic States

References

• Lohning M, Grogan JL, Coyle AJ, et al. T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. J Immunol. 1999;162:3882–3889.
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369–26380. doi:10.1074/jbc.M704916200
   PubMed Web of Science ®Google Scholar
• Mun SH, Ko NY, Kim HS, et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci. 2010;67:3883–3892. doi:10.1007/s00018-010-0410-y
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183:6469–6477. doi:10.4049/jimmunol.0901575
   PubMed Web of Science ®Google Scholar
• Joshi AD, Oak SR, Hartigan AJ, et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010;11:52. doi:10.1186/1471-2172-11-52
   PubMed Web of Science ®Google Scholar
• Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367–1370. doi:10.1038/nature08900
   PubMed Web of Science ®Google Scholar
• Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463:540–544. doi:10.1038/nature08636
   PubMed Web of Science ®Google Scholar
• Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123:1047–1054. doi:10.1016/j.jaci.2009.02.026
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Sumpter TL, Tsung A, et al. IL-1β-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol. 2008;181:62–72. doi:10.4049/jimmunol.181.1.62
   PubMed Web of Science ®Google Scholar
• Xu K, Williams RM, Holowka D, Baird B. Stimulated release of fluorescently labeled IgE fragments that efficiently accumulate in secretory granules after endocytosis in RBL-2H3 mast cells. J Cell Sci. 1998;111(Pt 16):2385–2396.
   PubMedGoogle Scholar
• Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998;95:6930–6935. doi:10.1073/pnas.95.12.6930
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an Interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490
   PubMed Web of Science ®Google Scholar
• Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–1030. doi:10.1093/intimm/dxn060
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Iikura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981–5989. doi:10.4049/jimmunol.181.9.5981
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Koketsu R, Iikura M, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008;88:1245–1253. doi:10.1038/labinvest.2008.82
   PubMed Web of Science ®Google Scholar
• Alves-Filho JC, Sonego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16:708–712. doi:10.1038/nm.2156
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Gilchrist DS, McKenzie AN, Goodyear CS, Xu D, Liew FY. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol. 2011;186:2584–2591. doi:10.4049/jimmunol.1002103
   PubMed Web of Science ®Google Scholar
• Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009;39:1046–1055. doi:10.1002/eji.200838575
   PubMed Web of Science ®Google Scholar
• Trajkovic V, Sweet MJ, Xu D. T1/ST2–an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15:87–95. doi:10.1016/j.cytogfr.2004.02.004
   PubMed Web of Science ®Google Scholar
• Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7:308ra160. doi:10.1126/scitranslmed.aab0166
   PubMed Web of Science ®Google Scholar
• Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787–794. doi:10.1084/jem.187.5.787
   PubMed Web of Science ®Google Scholar
• Yang Q, Li G, Zhu Y, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol. 2011;41:3351–3360. doi:10.1002/eji.201141629
   PubMed Web of Science ®Google Scholar
• Bonilla WV, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. 2012;335:984–989. doi:10.1126/science.1215418
   PubMed Web of Science ®Google Scholar
• Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564–568. doi:10.1038/nature13577
   PubMed Web of Science ®Google Scholar
• Matta BM, Reichenbach DK, Zhang X, et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016;128:427–439. doi:10.1182/blood-2015-12-684142
   PubMed Web of Science ®Google Scholar
• Blom L, Poulsen BC, Jensen BM, Hansen A, Poulsen LK. IL-33 induces IL-9 production in human CD4+ T cells and basophils. PLoS One. 2011;6:e21695. doi:10.1371/journal.pone.0021695
   PubMed Web of Science ®Google Scholar
• Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676–686. doi:10.1038/ni.2920
   PubMed Web of Science ®Google Scholar
• Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol. 2014;134:1422–1432. doi:10.1016/j.jaci.2014.05.011
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104:282–287. doi:10.1073/pnas.0606854104
   PubMed Web of Science ®Google Scholar
• Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3:e3331. doi:10.1371/journal.pone.0003331
   PubMed Web of Science ®Google Scholar
• Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–658. doi:10.1161/CIRCRESAHA.110.218867
   PubMed Web of Science ®Google Scholar
• Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, Taylor JJ. Expression and regulation of interleukin-33 in human monocytes. Immunology. 2010;130:172–180. doi:10.1111/j.1365-2567.2009.03221.x
   PubMedGoogle Scholar
• Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420–19426. doi:10.1074/jbc.M901744200
   PubMed Web of Science ®Google Scholar
• Ohno T, Oboki K, Kajiwara N, et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol. 2009;183:7890–7897. doi:10.4049/jimmunol.0802449
   PubMed Web of Science ®Google Scholar
• Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110–113. doi:10.1038/nature10134
   PubMed Web of Science ®Google Scholar
• Yanagawa Y, Suzuki M, Matsumoto M, Togashi H. Prostaglandin E(2) enhances IL-33 production by dendritic cells. Immunol Lett. 2011;141:55–60. doi:10.1016/j.imlet.2011.07.005
   PubMedGoogle Scholar
• Drake LY, Kita H. IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 2017;278:173–184. doi:10.1111/imr.12552
   PubMed Web of Science ®Google Scholar
• Lee JS, Seppanen E, Patel J, Rodero MP, Khosrotehrani K. ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Exp Dermatol. 2016;25:71–74. doi:10.1111/exd.12833
   PubMed Web of Science ®Google Scholar
• Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676–689. doi:10.1038/nri.2016.95
   PubMed Web of Science ®Google Scholar
• Liu X, Xiao Y, Pan Y, Li H, Zheng SG, Su W. The role of the IL-33/ST2 axis in autoimmune disorders: friend or foe? Cytokine Growth Factor Rev. 2019;50:60–74. doi:10.1016/j.cytogfr.2019.04.004
   PubMed Web of Science ®Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway–A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131:179–186. doi:10.1016/j.pharmthera.2011.02.005
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205:339–346. doi:10.1084/jem.20071868
   PubMed Web of Science ®Google Scholar
• Hasan A, Al-Ghimlas F, Warsame S, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 2014;15:19. doi:10.1186/1471-2172-15-19
   PubMed Web of Science ®Google Scholar
• A KS H, Al-Ozairi E, Tuomilehto J, Ahmad R. Association between adipose tissue interleukin-33 and immunometabolic markers in individuals with varying degrees of glycemia. Dis Markers. 2019.
   Google Scholar
• Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes. 2017;9:320–324. doi:10.1111/1753-0407.12524
   PubMed Web of Science ®Google Scholar
• American diabetes association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81–S90. doi:10.2337/dc14-S081
   PubMed Web of Science ®Google Scholar
• Gillett MJ. International expert committee report on the role of the A1c assay in the diagnosis of diabetes: diabetes care 2009; 32(7):1327–1334. Clin Biochem Rev. 2009;30:197–200.
   PubMedGoogle Scholar
• Ahmad R, Shihab PK, Thomas R, et al. Increased expression of the interleukin-1 receptor-associated kinase (IRAK)-1 is associated with adipose tissue inflammatory state in obesity. Diabetol Metab Syndr. 2015;7:71. doi:10.1186/s13098-015-0067-7
   PubMed Web of Science ®Google Scholar
• Tourniaire F, Romier-Crouzet B, Lee JH, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-κB. PLoS One. 2013;8:e66515. doi:10.1371/journal.pone.0066515
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115–124. doi:10.1172/JCI24335
   PubMed Web of Science ®Google Scholar
• Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–1505. doi:10.1172/JCI26498
   PubMed Web of Science ®Google Scholar
• Keophiphath M, Rouault C, Divoux A, Clement K, Lacasa D. CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler Thromb Vasc Biol. 2010;30:39–45. doi:10.1161/ATVBAHA.109.197442
   PubMed Web of Science ®Google Scholar
• Ferrante AW. Macrophages, fat, and the emergence of immunometabolism. J Clin Invest. 2013;123:4992–4993. doi:10.1172/JCI73658
   PubMedGoogle Scholar
• Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15:930–939. doi:10.1038/nm.2002
   PubMed Web of Science ®Google Scholar
• Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–920. doi:10.1038/nm.1964
   PubMed Web of Science ®Google Scholar
• Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15:921–929. doi:10.1038/nm.2001
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490
   PubMed Web of Science ®Google Scholar
• Li M, Li Y, Liu X, Gao X, Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol. 2012;247:25–31. doi:10.1016/j.jneuroim.2012.03.016
   PubMedGoogle Scholar
• Jiang HR, Milovanovic M, Allan D, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol. 2012;42:1804–1814. doi:10.1002/eji.201141947
   PubMed Web of Science ®Google Scholar
• Matta BM, Lott JM, Mathews LR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol. 2014;193:4010–4020. doi:10.4049/jimmunol.1400481
   PubMed Web of Science ®Google Scholar
• Chan CW, Kay LS, Khadaroo RG, et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol. 2003;170:4036–4044. doi:10.4049/jimmunol.170.8.4036
   PubMed Web of Science ®Google Scholar
• Shalev I, Wong KM, Foerster K, et al. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology. 2009;49:387–397. doi:10.1002/hep.22684
   PubMed Web of Science ®Google Scholar
• Foerster K, Helmy A, Zhu Y, et al. The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol. 2010;53:608–615.
   PubMedGoogle Scholar
• Zhao Z, Yang C, Wang L, et al. The regulatory T cell effector soluble fibrinogen-like protein 2 induces tubular epithelial cell apoptosis in renal transplantation. Exp Biol Med. 2014;239:193–201.
   Google Scholar
• Shalev I, Liu H, Koscik C, et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol. 2008;180:249–260. doi:10.4049/jimmunol.180.1.249
   PubMed Web of Science ®Google Scholar
• Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014;10:24–36. doi:10.1038/nrendo.2013.204
   PubMed Web of Science ®Google Scholar
• Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19:1252–1263. doi:10.1038/nm.3361
   PubMed Web of Science ®Google Scholar
• Brestoff JR, Kim BS, Saenz SA, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015;519:242–246. doi:10.1038/nature14115
   PubMed Web of Science ®Google Scholar
• Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab. 2010;11:253–256. doi:10.1016/j.cmet.2010.03.004
   PubMed Web of Science ®Google Scholar
• Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008;454:961–967. doi:10.1038/nature07182
   PubMed Web of Science ®Google Scholar
• Seale P, Kajimura S, Yang W, et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab. 2007;6:38–54. doi:10.1016/j.cmet.2007.06.001
   PubMed Web of Science ®Google Scholar
• Kajimura S, Seale P, Tomaru T, et al. Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev. 2008;22:1397–1409. doi:10.1101/gad.1666108
   PubMed Web of Science ®Google Scholar
• Kajimura S, Seale P, Kubota K, et al. Initiation of myoblast to brown fat switch by a PRDM16–C/EBP-β transcriptional complex. Nature. 2009;460:1154–1158. doi:10.1038/nature08262
   PubMed Web of Science ®Google Scholar
• Christian M, Parker MG. The engineering of brown fat. J Mol Cell Biol. 2010;2:23–25. doi:10.1093/jmcb/mjp035
   PubMedGoogle Scholar
• Cummins TD, Holden CR, Sansbury BE, et al. Metabolic remodeling of white adipose tissue in obesity. Am J Physiol Endocrinol Metab. 2014;307:E262–77. doi:10.1152/ajpendo.00271.2013
   PubMedGoogle Scholar
• Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42:358–364. doi:10.1016/j.cyto.2008.03.008
   PubMed Web of Science ®Google Scholar
• Zhao J, Wei J, Bowser RK, Traister RS, Fan MH, Zhao Y. Focal adhesion kinase-mediated activation of glycogen synthase kinase 3beta regulates IL-33 receptor internalization and IL-33 signaling. J Immunol. 2015;194:795–802. doi:10.4049/jimmunol.1401414
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640–643. doi:10.1126/science.1087262
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6:644–658. doi:10.1038/nri1900
   PubMed Web of Science ®Google Scholar
• Paun A, Pitha PM. The IRF family, revisited. Biochimie. 2007;89:744–753. doi:10.1016/j.biochi.2007.01.014
   PubMedGoogle Scholar
• Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584. doi:10.1146/annurev.immunol.26.021607.090400
   PubMed Web of Science ®Google Scholar
• Negishi H, Ohba Y, Yanai H, et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A. 2005;102:15989–15994. doi:10.1073/pnas.0508327102
   PubMed Web of Science ®Google Scholar
• Trama J, Lu Q, Hawley RG, Ho SN. The NFAT-related protein NFATL1 (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner. J Immunol. 2000;165:4884–4894. doi:10.4049/jimmunol.165.9.4884
   PubMed Web of Science ®Google Scholar
• Burg MB, Kwon ED, Kultz D. Regulation of gene expression by hypertonicity. Annu Rev Physiol. 1997;59:437–455. doi:10.1146/annurev.physiol.59.1.437
   PubMed Web of Science ®Google Scholar
• Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32:1771–1776. doi:10.1161/ATVBAHA.111.241869
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A. Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity. 2001;15:47–58.
   PubMed Web of Science ®Google Scholar
• Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20:2476–2489. doi:10.1038/sj.onc.1204386
   PubMed Web of Science ®Google Scholar
• Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472–484. doi:10.1038/nri1632
   PubMed Web of Science ®Google Scholar
• Hsu CL, Bryce PJ. Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. J Immunol. 2012;189:3421–3429. doi:10.4049/jimmunol.1201224
   PubMedGoogle Scholar
• Berga-Bolanos R, Alberdi M, Buxade M, Aramburu J, Lopez-Rodriguez C. NFAT5 induction by the pre-T-cell receptor serves as a selective survival signal in T-lymphocyte development. Proc Natl Acad Sci U S A. 2013;110:16091–16096. doi:10.1073/pnas.1215934110
   PubMedGoogle Scholar